Achieving a good efficacy of chemotherapy is one of the major challenges still unresolved in oncological patients. The main limitation to the efficacy of chemotherapy is the multidrug-resistant (MDR) phenotype, a multiple cross-resistance towards different anticancer drugs.
On 29 June 2022, COST’s governing board, the Committee of Senior Officials (CSO) approved funding for six new COST Innovators Grants (CIGs). What is a COST Innovators Grant?
The Committee of Senior Officials (CSO), the General Assembly of the COST Association, has accepted Georgia and Ukraine as its latest members. On 30-31 March 2022, representatives of the COST Members met under the auspices of the French Presidency of the Council of the EU in Paris. Following a unanimous decision, both Georgia and Ukraine join the COST family which now has 40 Full Members.
The Australian government will utilise Tasmania's renewable energy potential through significant investment in an interconnector to bring hydroelectricity .